BioSpace News Archive

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that the first patient has been dosed with HPN217 in a Phase 1/2 clinical trial focused on relapsed, refractory multiple myeloma.

Magellan Health, Inc. announced that it will report its earnings for the first quarter ended on March 31, 2020 at approximately 6:30 a.m. Eastern on Monday, May 11, 2020. At 8 a.m. Eastern on the same day, Magellan’s management will host a conference call and webcast to discuss earnings and other information.

CareDx, Inc. announced the online delivery of the content originally meant for showcase at the now-postponed annual European Immunogenetics and Histocompatibility Conference that was scheduled for Apr 26-29, 2020 in Glasgow, Scotland.

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced positive immunogenicity data from its preclinical study for the Company’s COVID-19 Vaccine.

Preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed, including decreased requirement for supplemental oxygenation, higher lymphocyte counts and decreased CRP

Updated data continue to demonstrate a durable clinical benefit in both immunotherapy-naïve patients as well as those previously treated with an immunotherapy regimen

Data demonstrated superiority of both test arms in co-primary outcome measures of axial length and cycloplegic spherical equivalent refraction (SER) over control lenses at 12-month planned interim analysis

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2020 financial results prior to market open on Monday, May 11, 2020. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results. The conferenc

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase 1 clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (AMD). Patients in Cohort

Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to study its investigational drug, OT-101, for the treatment of COVID-19 pandemic. The proposed randomized, double-blind, placebo-controlled Phase 2 study is intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia in th